[ad_1]
LONDON – The chief executive of British pharmaceutical company AstraZeneca, Pascal Soriot, said Thursday that the effectiveness of the coronavirus vaccine could be attested before the end of the year, if testing resumes this week around the world.
Know more:The time of science is not that of political pressure for approval of a vaccine, scientists say
The investigation was suspended after one of the volunteers suffered a disease that could be related to the drug. The patient developed neurological symptoms associated with a rare inflammation in the spine called transverse myelitis.
During a conference call on the vaccine, identified by the WHO as the most promising against Covid-19, Soriot said that the temporary interruption of this type of research is very common. The difference, she noted, is that everyone is watching.
The CEO reported that AstraZeneca was unaware during testing. More tests are needed to determine if transverse myelitis was already present. The results must be reviewed by an independent safety committee, which will decide whether the investigation can be resumed.
